Human epidermal growth factor receptor 2 (HER2) is an oncogene targeted by several kinase inhibitors and therapeutic antibodies. Endosomal trafficking of many other receptor tyrosine kinases regulates their oncogenic signaling, but the prevailing view is that HER2 is retained on the cell surface. Here we reveal that in cancer cells Sortilin related receptor 1 (SORLA; SORL1) forms a complex with HER2 and regulates its subcellular distribution by promoting recycling of endosomal HER2 back to plasma membrane. Expression of SORLA in cancer cell lines and bladder cancers correlates with HER2 levels. Depletion of SORLA targets HER2 to late endosomal/lysosomal compartments, impairs HER2-driven signaling and in vivo tumor growth. SORLA silencing also disrupts normal lysosome function and sensitizes anti-HER2 therapy sensitive and resistant cancer cells to lysosome-targeting cationic amphiphilic drugs. These findings reveal potentially important SORLA-dependent endosomal trafficking-linked vulnerabilities in HER2-driven cancers.
Introduction
The human epidermal growth factor receptor 2 (HER2; also known as ErbB2) is a receptor tyrosine kinase and a well-established oncogene. HER2 amplification is found in 15-30 % of breast cancers 1, 2 , and HER2 overexpression or activating mutations are clinically relevant in other solid tumors, such as bladder cancer, and colorectal, gastric and lung adenocarcinoma [3] [4] [5] . The biological relevance of HER2 as a driver oncogene is undisputed, and several targeted therapies have been approved for treating HER2-dependent cancers.
Several previous studies, including ours, demonstrate that oncogenic signaling and endosomal traffic of many receptor tyrosine kinases are functionally coupled [6] [7] [8] [9] . Endosomal trafficking critically controls, for instance, the strength and the duration of signaling by epidermal growth factor receptor (EGFR; also known as ErbB1) or MET 6, 10, 11 . However, in comparison to other receptor tyrosine kinases, the details of HER2 trafficking are poorly understood. The prevailing view, supported by two different models, is that HER2 resides almost exclusively on the plasma membrane in HER2amplified cancer cell lines 12 . Data in favor of a 'lack of internalization' model suggest that HER2 resists internalization due to 1) absence of identified ligands required for induction of endocytosis 12 , 2) absence of a recognizable internalization motif 12 , 3) inhibition of clathrin-coated pit formation 13 , 4 ) association with membrane protrusions 14 and 5) heat shock protein 90 (HSP90)-dependent stabilization of HER2 on the plasma membrane [15] [16] [17] . On the other hand, data in support of a model for 'rapid recycling' resulting in nearly exclusive cell-surface localization of HER2 have been brought forward [18] [19] [20] . Hence, the key outstanding questions are: does HER2 undergo endosomal trafficking in HER2-driven cancer cells, and what would the functional consequences of HER2 trafficking be for its oncogenic properties?
SORLA is a multifunctional intracellular sorting protein belonging to sortilin and LDL-receptor families consisting of a large extracellular domain, a transmembrane domain and a short cytoplasmic tail 21 , which is essential for its membrane sorting functions 22, 23 . SORLA has been implicated in regulating amyloid precursor protein (APP) processing during the pathogenesis of Alzheimer's disease (AD) [24] [25] [26] and in lipid metabolism and obesity 27, 28; 29, 30 . We made the unexpected observation that SORLA is highly expressed specifically in HER2-driven cancers where SORLA levels correlate with HER2 subcellular localization. We find that SORLA associates with HER2, and regulates its trafficking from intracellular compartments to the plasma membrane. Moreover, we show that SORLA is necessary for oncogenic HER2 signaling in vitro and in vivo. Depletion of SORLA induces lysosome dysfunction and results in mislocalization of signaling-defective HER2 to lysosomes. As a result, SORLA depletion halts tumorigenesis and sensitizes cancer cells to a clinically relevant lysosome-targeting drug. Taken together, our data demonstrate that SORLA has previously unrecognized oncogenic functions in carcinomas.
Results

SORLA associates and co-localizes with HER2 on the plasma membrane and intracellular vesicles
Analysis of different breast cancer cell lines revealed that SORLA protein was mainly expressed in those with HER2-amplification ( Fig. 1a ). SORLA was also highly expressed in the 5637 bladder cancer cell line harboring a HER2-activating mutation (S310F) 31 when compared to the HER2-low expressing T24 cell line and primary patient-derived bladder cancer cells ( Supplementary Fig. 1a ).
As SORLA has not previously been scrutinized in carcinoma cells, we first examined the subcellular localization of this sorting receptor in different endosomal compartments. SORLA was found to localize largely to early endosomes (identified by EEA-1-and Rab5-positive expression) and retrograde vesicles (VPS35) in breast cancer cells. SORLA-GFP fusion protein showed similar localization as endogenous SORLA to EEA1-and VPS35-positive vesicles ( Supplementary Fig. 1b) and was also present in recycling endosomes (Rab11) ( Supplementary Fig. 1b ) but did not overlap with late-endosome or lysosome markers Rab7 and LAMP1, respectively ( Supplementary Fig. 1b ).
Previous studies have indicated that HER2 is mainly restricted to the plasma membrane 12 , but these observations were based on a very limited number of cell lines and/or on exogenous overexpression of HER2 14, 18, 32 . Since SORLA is an important sorting protein in neuronal cells and adipocytes and is expressed in HER2-positive cancer cells ( Fig. 1a ), we were interested to re-examine the subcellular localization of endogenous HER2 in breast cancer cells with variable levels of SORLA expression ( Fig. 1a ). In the BT474 and SKBR3 cells with high SORLA expression, HER2 was mainly on the plasma membrane, in accordance with previous work 14, 18 , and did not overlap with EEA-1 positive endosomes ( Fig. 1a,b, Supplementary Fig. 1c ). A similar distribution was also detected in the third SORLA-high cell line HCC1419 ( Fig. 1a, Supplementary Fig. 1c ). However, in cells with intermediate (MDA-MB-361) or low/absent (HCC1954 and JIMT-1) SORLA, HER2 was also distributed intracellularly indicating that HER2 must be trafficking at least in a subset of HER2 cancers. In these cells, a proportion of the intracellular HER2 pool clearly overlapped with EEA-1 indicating localization in early endosomes ( Fig. 1b, Supplementary Fig. 1c ). In MDA-MB-361 cells endogenous SORLA co-localized with HER2 in EEA-1 positive early endosomes (Fig. 1c) , and in the SORLA negative JIMT-1 cells SORLA-GFP localized to HER2 and VPS35 positive intracellular vesicles ( Fig. 1c ). When SORLA-GFP expression was analyzed in JIMT-1 cells (n = 130), 19 .8±0.8 percent of SORLA-GFP overlapped with intracellular HER2 ( Supplementary Fig. 1d ) showing Pearson's R of 0.3±0.01 indicative of partial colocalisation.
To study whether SORLA and HER2 would show similar dynamics in cells, we chose to image the MDA-MB-361 cells expressing intracellular as well as cell surface pools of HER2. We performed live-cell TIRF imaging (allowing visualization of events close to the plasma membrane) of SORLA-GFP and HER2 labelled with an Alexa568-conjugated anti-HER2 antibody (trastuzumab; Tz-568).
Short-lived SORLA-and HER2-positive structures were detected in the TIRF-plane, indicative of active dynamics to and from the plasma membrane. In addition, co-localizing puncta of SORLA and HER2 were frequently observed undergoing dynamic lateral movement on the plasma membrane ( Fig. 1d , Supplementary video 1). Live-cell imaging deeper in the cytoplasm showed that SORLA and HER2 move together within the same endosomal structures ( Supplementary Fig. 1e and video 2). Collectively these data show that SORLA and HER2 undergo co-trafficking between the plasma membrane and endosomes.
Intrigued by the apparent co-trafficking of SORLA and HER2, we next performed a set of immunoprecipitation assays to investigate whether HER2 and SORLA associate. Endogenous HER2 co-precipitated endogenous SORLA in MDA-MB-361 and BT474 cells, indicating that HER2 and SORLA are in the same protein complex ( Fig. 1e ). SORLA consists of an extracellular domain (ECD), a transmembrane domain (TM) and a short cytosolic domain (CD) ( Fig. 1f ). To study the link between HER2 binding and different domains of SORLA in cells, we generated truncated SORLA-GFP fusions consisting of either the SORLA extracellular and transmembrane domains (ECD+TM) or the SORLA transmembrane and cytosolic domains (TM+CD) (Fig 1f, g) . HER2 associated with the full-length SORLA-GFP and SORLA-GFP ECD+TM in cells, but failed to associate with SORLA-GFP TM+CD (Fig. 1g ). Interestingly, SORLA-GFP TM+CD showed similar vesicular localization as full-length SORLA-GFP, whereas SORLA-GFP ECD+TM was found diffusely in membrane compartments in the cytoplasm and on the plasma membrane ( Supplementary Fig. 1f ).
Thus, SORLA ECD is necessary for association with HER2, whereas SORLA CD is responsible for correct subcellular localization of the protein.
SORLA regulates HER2 cell surface levels and HER2 oncogenic signaling
The apparent inverse correlation between SORLA levels and the proportion of intracellular HER2 in the different HER2 cell lines (Fig 1a, b Supplementary Fig. 1c ) prompted us to hypothesise that cell surface HER2 levels may be regulated by SORLA. To test this we performed loss-of-function experiments in SORLA-high BT474 cells and gain-of-function experiments in intermediate/negative SORLA cell lines MDA-MB-361 and JIMT-1 cells, respectively. In BT474 cells, with predominantly plasma membrane localized HER2 and high SORLA expression, silencing of SORLA led to, approximately, a 50 % decrease in cell-surface HER2 protein levels ( Fig. 2a ). Conversely, in the SORLA intermediate MDA-MB-361 and SORLA-negative JIMT-1 cells, in which HER2 localizes more to endosomal structures, SORLA overexpression significantly increased cell surface HER2 levels ( Fig. 2a ). Total HER2 protein levels followed a similar trend of being significantly downregulated in SORLA silenced BT474 cells and upregulated in SORLA-overexpressing MDA-MB-361 and JIMT-1 cells (Fig. 2b, c) . Quantitative PCR analysis of ErbB2 mRNA levels after SORLA silencing or overexpression did not show any significant difference indicating that SORLAmediated regulation of HER2 occurs predominantly at the post-transcriptional level ( Supplementary   Fig. 2a ).
HER2 amplification is a major driver of proliferation and tumorigenesis, which prompted us to explore whether SORLA plays a functional role in breast cancer cells. Efficient silencing of SORLA in HER2-amplified SORLA-high BT474 cells significantly reduced cell proliferation ( Fig. 2d , Supplementary Fig. 2b ). This was specifically due to loss of SORLA rather than off-target-effects given that silencing SORLA with five individual siRNAs significantly reduced proliferation in BT474 cells ( Supplementary Fig. 2c, d ). Conversely, in the SORLA negative JIMT-1 cells expression of SORLA-GFP, which triggered HER2 up-regulation on the plasma membrane ( Fig. 2a ), significantly increased proliferation of these cells ( Fig. 2e, Supplementary Fig. 2e ). When SORLA was silenced in non-HER2-amplified FGFR2-amplified MFM-223 breast cancer cells ( Fig. 1a ), there was no effect on cell proliferation ( Supplementary Fig. 2f ), indicating that SORLA is required for proliferation only in HER2-dependent cancer cells.
HER2 signaling on the plasma membrane along the PI3K/AKT pathway is critical for HER2 growth promoting functions in cancer cells. Silencing of SORLA in BT474 and MDA-MB-361 cells led to decreased phosphorylation of AKT (Ser473) and 4E-PB1 (Thr37/46) as well as decreased cyclin D1 levels, but did not inhibit mitogen-activated protein kinase (ERK1/2) signaling ( Fig. 2f Supplementary Fig. 2g ). Taken together these data suggest that SORLA silencing specifically attenuates cell proliferation and PI3K-dependent HER2 signaling in HER2-amplified cells.
To investigate further the requirement for SORLA for proliferation of HER2 cancer cells, we silenced SORLA in MDA-MB-361 cells with intermediate SORLA expression using a SORLA 3'UTR targeting siRNA and then re-expressed SORLA. Re-expression of SORLA-GFP in MDA-MB-361 cells fully rescued cell proliferation to control levels ( Fig. 2g, Supplementary Fig. 2h ). Importantly, only full-length SORLA-GFP, and not the HER2-associating SORLA-GFP ECD+TM or the correctly localizing but none-HER2-binding SORLA-GFP TM+CD, was sufficient to rescue the effect of SORLA silencing on MDA-MB-361 cell proliferation (Fig. 2h ). This suggests that SORLA association with HER2 and SORLA sorting functions are necessary for SORLA-mediated proliferation of HER2-dependent cancer cells.
Importantly, silencing SORLA compromised the in vivo tumor engraftment of HER2-amplified breast cancer cells in an orthotropic model. SORLA-silenced and control MDA-MB-361 cells were generated by transducing two short hairpin RNAs (shRNAs) targeting SORLA (shSORLA #1 and shSORLA #4) and a non-targeting control (shCTRL). Efficient SORLA silencing strongly inhibited in vitro proliferation of these cells ( Supplementary Fig. 2i , j). When control-silenced cells were injected into mammary ducts of immunocompromised NOD.SCID mice, multiple ductal carcinoma in situ (DCIS) lesions were formed within 10 weeks. In contrast, the development of DCIS tumors from SORLA-silenced xenografts was almost completely halted ( Fig. 2i ). Take together these data indicate that SORLA functionally regulates both the expression and oncogenic functions of HER2 in breast cancer.
SORLA promotes HER2 recycling
The steady-state distribution of cell surface receptors between endosomes and the plasma membrane is regulated by the respective rates of receptor internalization and recycling back to the plasma membrane. To study whether SORLA regulates this balance in HER2 cell lines, we investigated HER2 localization and trafficking in the presence and absence of SORLA. First, we silenced SORLA in BT474 cells, with high SORLA levels and predominantly plasma membrane HER2 at steady state.
Interestingly, shRNA-mediated SORLA silencing led to increased intracellular accumulation of HER2, normally not observed in these cells ( Fig. 3a, b ). A similar shift in HER2 subcellular localization was triggered when inhibiting vesicular recycling with primaquine, indicating that HER2 undergoes constant endocytosis balanced with very rapid recycling in cells with predominantly plasma membrane localized HER2 and that SORLA may play a role in facilitating this (Fig 3c, d ).
Next we investigated HER2 dynamics in MDA-MB-361 cells where HER2 is localized endosomally and on the plasma membrane and SORLA is expressed at intermediate levels. SORLA-silenced MDA-MB-361 cells were subjected to an imaging-based receptor uptake assay. Cell surface HER2 was labelled with Tz-568 on ice, after which internalization of Tz-568 was induced by incubating cells at +37 o C for 15 min, 30 min, and 60 min before fixing. SORLA-silenced cells showed significantly greater accumulation of intracellular HER2 after 15 min and 30 min of internalization when compared to control-silenced cells (Fig. 3e , f). Similar data was obtained with a biochemical internalization assay of HER2. SORLA-silenced MDA-MB-361 cells were cell surface biotinylated on ice with a cleavable biotin-conjugate. Internalization was induced by incubating cells at +37 o C for the indicated times and was followed by cleavage of cell surface retained biotin before cell lysis, HER2 immunoprecipitation and detection of biotinylated and total HER2 with anti-biotin and anti-HER2 antibodies, respectively. In line with the imaging-based internalization analyses, loss of SORLA resulted in increased intracellular accumulation of HER2 at 30 min internalization ( Fig. 3g ), indicating that the outcome of the imaging-based internalization assays was not secondary to trastuzumab-induced HER2 uptake 18 . In most systems, receptor endocytosis is most prominent immediately after synchronized internalization and reaches a plateau after 10 minutes in cells where receptor recycling is unperturbed. Since SORLA silencing caused delayed HER2 accumulation inside MDA-MB-361 cells and the recycling inhibitor primaquine triggered intracellular accumulation of HER2 in BT474 cells, we hypothesized that SORLA could regulate the recycling step of HER2 trafficking. To test this in more detail, we utilized JIMT-1 cells which do not express endogenous SORLA, contain a substantial fraction of intracellular HER2 at steady state and where overexpression of SORLA leads to increased HER2 cell surface levels (Fig 2a) . Overexpression of SORLA-GFP in JIMT-1 cells inhibited intracellular accumulation of cell surface biotinylated HER2 when compared to control transfected cells ( Fig. 3h ). Furthermore, a biochemical recycling assay, in which biotin is cleaved off from an internalized biotinylated receptor upon recycling back to the plasma membrane, revealed that SORLA-GFP-expressing JIMT-1 cells had a higher rate of HER2 recycling when compared to JIMT-1 control cells ( Fig. 3i ). Taken together, these findings demonstrate a new role of SORLA in regulation of HER2 recycling.
Silencing SORLA triggers HER2 accumulation in dysfunctional lysosomes
As SORLA silencing triggered increased intracellular retention of HER2 in the internalization assays, we wanted to investigate the subcellular localization of HER2 in SORLA-silenced MDA-MB-361 cells. Imaging revealed striking accumulation of HER2 in enlarged LAMP-1-positive structures (late endosomes/lysosomes), not observed in control cells ( Fig. 4a , Supplementary Fig. 3a ). This unexpected intracellular distribution could be linked to the specific attenuation of PI3K/AKT signaling in SORLA-silenced cells ( Fig. 2f , Supplementary Fig. 2g ) since the ligand for PI3K, PI(4,5,)P2, is predominantly enriched on the plasma membrane and considered to be absent in late endosomes, thus restricting signaling of the lysosomally localized HER2 through the PI3K/AKT pathway. The accumulation of HER2 in enlarged LAMP-1-positive structures in SORLA-silenced cells was striking as normally lysosomal targeting of growth factor receptors is linked to their rapid degradation. However, on the other hand, HER2 protein levels in SORLA-silenced cells were only modestly reduced ( Supplementary Fig. 3a ). This apparent discrepancy lead us to investigate whether loss of SORLA could be linked to potentially abnormal lysosome function. Supplementary Fig. 3d ). Thus, depletion of endogenous SORLA in breast cancer cells leads to altered subcellular localization of lysosomes.
Next we wanted to investigate if the observed lysosome phenotype is linked to decreased HER2 function. Silencing HER2 with two individual siRNAs affected lysosome localization similarly, but to a lesser extent, than SORLA silencing in BT474 and MDA-MB-361 cells (supplementary Fig 3e, f). When SORLA was silenced in non-HER2-amplified FGFR2-amplified MFM-223 breast cancer cells ( Fig. 1a ), there was no effect on lysosomal distribution/localization ( Supplementary Fig. 3g ).
Thus, the lysosome phenotype seems to be linked to the absence of SORLA or HER function in HER2-dependent cells and to impaired cell growth.
Further analyses using transmission electron microscopy (TEM) revealed enlarged lysosomes in SORLA-silenced cells suggesting potential lysosome maturation defects ( Fig. 4d ). To monitor the proteolytic activity of lysosomes, we analyzed loss of quenching of a fluorogenic protease substrate, DQ Red BSA, loaded into cells 33 . SORLA-silenced MDA-MB-361 cells showed significantly lower DQ Red BSA signal (indicating reduced lysosomal cleavage of BSA), detected either by confocal microscopy imaging (supplementary Fig 3h) or by flow cytometry (Fig. 4e ), than the respective control cells. These data together indicate a link between SORLA-dependent HER2 signaling and lysosome integrity in HER2-driven cancer cells.
Depletion of SORLA renders HER2-driven cancer cells sensitive to CADs
Previous studies indicate that cancer cells possess functionally abnormal lysosomes making them more susceptible to cationic amphiphilic drugs (CADs), a heterogeneous class of molecules with a similar chemical structure resulting in lysosomal accumulation and increased lysosomal membrane permeabilization 34 . Recently, cancer cells were shown to be more sensitive to CAD-induced cell death than non-transformed cells 35 . Given the defective lysosome integrity of SORLA-depleted cells, we wanted to evaluate the response of anti-HER2 therapy sensitive BT474 and therapy-resistant MDA-MB-361 cells to antihistamine ebastine, a CAD with cytotoxic effects in lung cancer 35 .
Interestingly, the ebastine IC50 values, for inhibiting cell viability, were significantly lower in both of these HER2-amplified breast cancer cell lines when SORLA was silenced compared to control cells ( Fig. 4f ). Moreover, treatment of SORLA-silenced MDA-MB-361 cells with 15 µM ebastine, which is close to the determined IC50 value that inhibits the growth of these cells, significantly increased levels of cleaved PARP1, indicative of apoptosis, whereas no such effect was seen in control-silenced cells ( Fig. 4g ,h). Thus, deletion of SORLA increased the sensitivity of anti-HER2 therapy sensitive and resistant breast cancer cells to CADs, presumably due to apoptosis triggered by lysosomal dysfunction. These data indicate that compromised lysosomal integrity of SORLAsilenced cells could be exploited therapeutically to induce cell death of HER2-therapy resistant breast cancer cells.
SORLA correlates with HER2 and regulates proliferation and tumor growth in bladder cancer
Our in vitro data and observations of reduced tumor formation in mice demonstrate an important role for SORLA in regulation of HER2 function in breast cancer cells. To broaden our study for other cancer types in which HER2 overexpression is common and clinically relevant 36, 37 , we stained SORLA in a bladder cancer tissue microarray (TMA) of 199 patients. In this cancer type HER2 and SORLA levels correlated significantly (Chi-square test. p = 0.0092), whereas there was no correlation between SORLA and EGFR ( Fig. 5a , Supplementary Fig. 4a ). This led us to test if SORLA also plays a role in the regulation of bladder cancer cell proliferation and in vivo tumor growth. Silencing of SORLA in 5637 cells, a bladder carcinoma cell line with a HER2 signaling activating mutation 31 , significantly inhibited their proliferation (Fig. 5b,c) . Moreover, subcutaneous grafting of transiently SORLA-silenced 5637 cells (the strong anti-proliferative effect of shSORLA in vitro precluded sufficient propagation of stably silenced cells for in vivo experiments), in Nude mice resulted in impaired tumor growth (mean tumor volumes of 78.7 mm 3 and 47.7 mm 3 (p=0.0461) with control and SORLA-silenced cells, respectively) ( Fig. 5d , Supplementary Fig. 4b ).
Furthermore, SORLA-silenced 5637 tumors showed decreased proliferation, but not significantly increased apoptosis (Fig. 5e ). These results demonstrate that SORLA-mediated regulation of proliferation is not only restricted to HER2-amplified breast cancers, but is biologically important at least in HER2-driven urothelial cancer. It may also be relevant to other neoplasms considering that data mining of the TCGA database revealed a significant positive correlation between ErbB2 and SORL1 expression in testicular germ cell tumors, cervical squamous cell carcinoma and endocervical adenocarcinoma, kidney renal clear cell carcinoma, sarcoma and thymoma ( Supplementary Fig. 4c ).
Discussion
Here we demonstrate that SORLA, a sorting protein previously not investigated in carcinomas, is highly expressed in many HER2-driven cancer cell lines, and that SORLA regulates HER2 subcellular localization by associating with the receptor and coupling it to the recycling machinery ( Fig. 5f ). We find that HER2 distribution between the plasma membrane and endosomes is highly heterogeneous in cancer cells and those with lower SORLA expression exhibit a trend of harboring a substantial pool of intracellular HER2 at steady state. Furthermore, silencing of SORLA induces intracellular accumulation of HER2, and overexpressing SORLA triggers cell-surface localization of HER2. Thus, HER2 undergoes rapid endosomal traffic and recycling, the kinetics of which is regulated by SORLA-HER2 association. The fact that interfering with SORLA 1) dramatically reduced proliferation of HER2-driven bladder and breast cancer cells in vitro and in vivo, 2) altered HER2 signaling, 3) interfered with lysosome integrity and 4) had additive pro-apoptotic effects in combination with a clinically well-tolerated and widely used lysosome accumulating drug provides new insight into the pathophysiology and targetability of HER2-driven oncogenesis.
Previous studies have shown discrepant results regarding HER2 trafficking. While some studies have shown that HER2 is resistant to internalization 13, 14, 32 , others have suggested rapid recycling of HER2 back to plasma membrane 19 . In both scenarios, HER2 is mainly restricted to the plasma membrane where it can associate with signaling platforms to drive the proliferation and tumorigenesis of cancer The sorting functions of SORLA have been implicated in Alzheimer's disease and obesity [24] [25] [26] 30 .
We found that the ECD of SORLA associates with HER2, while the intracellular domain of SORLA is required for the correct endosomal and plasma membrane localization of SORLA in cancer cells.
Importantly, re-expression of neither ECD-TM nor TM-CD truncation mutants of SORLA were sufficient to support proliferation of SORLA-silenced cells. This suggests that both the ECD association with HER2 and the correct subcellular localization of the SORLA-HER2 complex are necessary for proper SORLA function in supporting HER2-driven oncogenesis.
Lysosomal function is strongly linked to cellular fitness and it is especially important for the nutrient balance in rapidly growing cancer cells. One important finding of our work is that SORLA plays a major and unanticipated role in maintenance of lysosome function in HER2-dependent cancer cells, but not in the FGFR2-amplified, SORLA-positive MFM-223 cancer cells. The effects of SORLA depletion on the lysosome function were two-fold. Lysosomes in SORLA-silenced cells showed perinuclear clustering. This was phenocopied to some extent by HER2 silencing in the same cells, in line with previous reports 40, 41 . In addition, we found that lysosomes were enlarged, displayed an abnormal maturation defect-like appearance and had reduced proteolytic activity in SORLA-depleted cells. Strikingly, after SORLA silencing, HER2 accumulated into lysosomes without being efficiently degraded ( Fig. 5f ). This is in stark contrast to the rapid lysosomal degradation of HER2 following treatment with geldanamycin, which inhibits HSP90-CDC37 complex mediated stabilization of HER2 on the plasma membrane 42, 43 and suggests that SORLA regulates HER2 in a fundamentally distinct way than HSP90. Possibly due to the mistargeted localization and lack of suitable signaling co-factors on late endosomes, HER2 signaling to the PI3K/AKT/mTOR proliferative pathway was decreased in SORLA-silenced cells. However, lysosomal aggregation triggered by HER2 silencing was not as dramatic as that induced by SORLA silencing. To us this implies that SORLA also contributes to lysosome function via HER2-independent mechanisms. The possible role of SORLAdependent alteration of lipid and glucose metabolism [27] [28] [29] [30] in lysosomal dysfunction remains to be investigated.
We found that SORLA-silenced cells undergo apoptosis when exposed to low doses of the antihistamine ebastine, which belongs to a heterogeneous group of molecules, CADs, with similar chemical features 44 and with a tendency to accumulate strongly to leaky lysosomes that are common in transformed cells 34, 35 . CADs, including ebastine, have been utilized in several in vitro, pre-clinical and clinical trials to target the vulnerability of lysosomes in cancer 35 . Importantly, we found that both anti-HER2 therapy resistant and sensitive HER2-amplified breast cancer cells are sensitive to the combination of SORLA silencing and low doses of ebastine. Silencing SORLA alone mainly reduced proliferation, but when combined with ebastine triggered enhanced apoptosis. This additive effect could potentially be exploited by combining current anti-HER2 therapies with CADs, since breast cancer cells and patient-derived xenografts resistant to anti-HER2 drug-antibody conjugate were recently shown to possess dysfunctional lysosomes 45 .
In conclusion, we have discovered that SORLA regulates the subcellular localization of HER2 and that dynamic recycling is essential for the oncogenic fitness of HER2. The endosomal trafficking of HER2 could provide new rationale for designing novel targeted therapies and understanding the resistance mechanisms induced by the current HER2-targeting therapies.
Methods
Methods are included in the supplementary information and any relevant references are provided in the reference list of the manuscript 
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Methods
Subcutaneous and Ductal carcinoma in situ (DCIS) in vivo xenograft models
For subcutaneous (s.c.) tumors, 2 million siCTRL and siSORLA #3 treated 5637 bladder cancer cells were injected s.c. in 100 µl (50% Matrigel, 50% PBS) at the flank of 6 weeks old Nude mice. Mice were sacrificed after 29 days, and tumors were dissected, fixed in 10% formalin, and processed for paraffin sections with standard protocols. Sections were stained with hematoxylin-eosin (HE) and immunohistochemistry (IHC) for proliferation (Ki67) and apoptosis (TUNEL) markers. Sections were imaged with pannoramic slide scanner. 
Lentiviral transduction to generate stable cell lines.
To generate stable silenced cell lines 4x10 5 
Western blot analysis
Protein extracts were separated using SDS-PAGE under denaturing conditions (4-20% Mini-PROTEAN TGX Gels) and were transferred to the nitrocellulose membrane (Bio-Rad Laboratories).
Membranes were blocked with 5% milk-TBST (Tris-buffered saline and 0.1% Tween 20), incubated with the indicated primary antibodies overnight at +4°C. Primary antibodies were diluted in blocking buffer (Thermo, StartingBlock (PBS) blocking, Product#37538) and PBS (1:1 ratio) mix and incubated overnight at +4 o C. Primary antibody dilutions used ranged from 1:500 to 1:1000. After primary antibody incubation, membranes were washed three times with TBST and incubated with fluorophore-conjugated secondary antibodies were diluted (1:1000) in the blocking buffer at RT for 1 h. Membranes were scanned using an infrared imaging system (Odyssey; LI-COR Biosciences).
The following secondary antibodies were used: donkey anti-mouse IRDye 800CW (LI-COR, 926-32212), donkey anti-mouse IRDye 680RD (LI-COR, 926-68072), donkey anti-rabbit IRDye 800CW (LI-COR, 926-32213), donkey anti-rabbit IRDye 680RD (LI-COR, 926-68073).
Co-immunoprecipitations
Non-transfected cells or cell transfected as indicated were lysed in IP-lysis buffer (0.5% Triton X- 
Transmission electron microscopy
The cells were fixed in 5% glutaraldehyde in 0.16 M s-collidine buffer, pH 7.4. The samples were post-fixed for 2 h with 1% OsO4 containing 1.5% potassium ferrocyanide, dehydrated with a series of increasing ethanol concentrations and embedded in 45359 Fluka Epoxy Embedding Medium kit. 70-nm sections were cut with an ultramicrotome, and stained with 1% uranyl acetate and 0.3% lead citrate. The sections were examined with a JEOL JEM-1400 Plus transmission electron microscope.
Live-cell imaging
Lentiviral transduced SORLA-GFP expressing MDA-MB-361 cells were kept on ice and washed twice with ice cold PBS. Alexa-567-conjugated trastuzumab (0.15 g/ml) in Hank's Balanced Salt Solution was incubated with the cells on ice for 1 hr protected from light. The cells were washed twice with ice cold PBS before adding pre-warmed culture media supplemented with 5% HEPES (without serum). Imaging was performed with Deltavision OMX V4 total internal reflection microscopy (TIRFM; GE Healthcare) every 250 ms with 60x/1.49 objective (Olympus TIRF objective).
Proliferation assay
Cells, transfected as indicated, were plated on 96-well plate (3000 cells/well) in volume of 100 µl. 
Analysis of cell surface HER2 levels by flow cytometry
DQ Red BSA assay
For microscopy assays, silenced cells were plated on ibidi 8-well µ-slide 72 hours post-transfection.
On the next day, the medium was replaced with DQ Red BSA (ThermoScientific, D12051)containing media (25 µg/ml, 200 ul/well) and cells were incubated for 48 h at 37 o C with 5 % CO2, the cells were washed, fixed with 4 % PFA for 10 minutes at room temperature, washed again and imaged with Carl Zeiss LSM780 laser scanning confocal microscope.
For flow cytometric assays, the cells were silenced and loaded with DQ Red BSA (25 µg/ml, 1 ml per well in 6-well plate for 24 h) as above. When indicated, 25 nm bafilomycin (Calbiochem, 196000-10UG) or DMSO only was added to DQ Red BSA and the loading was shortened to 4 h. The loaded cells were detached with HyQtase, washed, fixed with 4 % PFA for 15 min at room temperature, washed, and analyzed using LSRFortessa (BD Biosciences) and Flowing software. Fluorescence signals from unstained cells (background) were subtracted from the DQ Red BSA signals and geometric means were plotted.
RNA extraction, cDNA synthesis and qPCR
Cells were lysed in RA lysis buffer and RNA was extracted according to manufacturer's instructions (NucleoSpin RNA extraction kit, Macherey-Nagel, 740955.5). RNA concentrations were measured by NanoDrop Lite (Thermo). Complementary DNA (cDNA) was synthesized using a high-capacity cDNA Reverse Transcription Kit (Applied Biosystems) according to the manufacturer's instructions. Thereafter, the cells were allowed to internalize receptors in prewarmed 10% serum-containing medium at +37°C for the indicated times. Internalization was stopped by transferring the cells on ice and adding cold media. The remaining biotin on the cell surface was removed with 60 mM MesNa (63705; sodium 2-mercaptoethanesulfonate: Fluka) in MesNa buffer (50 mM Tris-HCl [pH 8.6], 100 mM NaCl) for 30 min at 4°C, followed by quenching with 100 mM iodoacetamide (IAA, Sigma) for 15 min on ice. To detect the total surface biotinylation, plates were left on ice after the biotin labelling and MesNa treatment was omitted. Cells were then washed with PBS, scraped in lysis buffer (50 mM Tris pH 7.5, 1.5 % Triton X-100, 100 mM NaCl, complete, and phosphatase inhibitors [Mediq; Roche]) at 4°C for 20 min. After clarification by centrifugation (14,000 × g, 10 min, 4°C), HER2 was immunoprecipitated from the supernatants with appropriate antibodies and protein G sepharose beads (17-0618-01; GE Healthcare). The immunoprecipitates were eluted in non-reducing Laemmli sample buffer and subjected to Western blotting as described above. Biotinylated (internalized) HER2 and total receptor levels were detected by immunoblotting with horseradish peroxidase (HRP)-conjugated anti-biotin antibody (#7075; Cell Signaling Technology) and receptorspecific antibodies, respectively. Enhanced chemiluminescence-detected biotin and receptor signals were quantified as integrated densities of protein bands with ImageJ (v. 1.43u), and each biotin signal was normalized to the corresponding receptor and total biotin signals.
HER2 recycling assay in JIMT-1 SORLA-GFP cells
HER2 recycling was measured using a cell-surface biotinylation-based assay as previously described 47 . Cell surface proteins were biotinylated and allowed to be internalized as described above for endocytosis assay for 30 min. After the first MesNa/IAA treatment, receptor recycling was triggered by treating the cells with prewarmed media containing 10% FBS at +37°C for the indicated time followed with a second MesNa/IAA treatment cleaving biotin from cell surface recycled proteins.
HER2 was immunoprecipitated and analysed for biotinylation and total levels as in the endocytosis assay. For TUNEL staining of apoptotic cells, endogenous peroxidase activity was blocked with incubation in 3% H2O2 in PBS for 15 min. The reaction mix containing recombinant terminal transferase (Cat No. 03 333 566 001, Roche), CoCl2 and Biotin-16-dUTP (11 093 070 910, Roche) in TdT buffer (1M Potassium cacodylate, 3% BSA in PBS, pH 6.6) was applied on slides and incubated for 1 h at +37ºC in a humidified chamber. As a positive control, one section was incubated for 30 min in DNAse solution at +37ºC before TUNEL staining, and as a negative control, the reaction mix was added without the transferase. Then the samples were incubated with End reaction-solution (300mM NaCl, 30 mM Sodium Citrate) for 30 min at RT and washed. Blocking was done with 3% BSA in PBS 45 min at RT after which the samples were incubated with ExtrAvidine (1:500 dilution in 1% BSA/PBS) for 30 min at +37ºC in a humidified chamber. After PBS washes, DAB solution (DAKO K3468) was added for 10 sec followed by washing. After counterstain with Mayer's HTX, the slides were dehydrated, cleared in xylene, mounted and imaged with Pannoramic 250 Slide Scanner (3DHISTECH Ltd).
Imaging-based trastuzumab internalization assay
For bladder cancer tissue microarray (TMA) immunohistochemistry, BenchMark XT automated IHC/ISH slide staining system (Ventana Medical Systems, Inc.) with Cell Conditioning Solution (CC1) as a pretreatment was used for anti-HER2/neu (rabbit monoclonal, Ventana clone 4B5, 24 min incubation) and anti-EGFR (rabbit monoclonal, Ventana clone 5B7, 32 min), followed by UltraView Universal DAB Detection Kit (Ventana). For SORLA staining, antigen retrieval pretreatment was first done by microwaving the slides in citrate buffer (pH 6). Lab Vision autostainer (Thermo Fisher Scientific) with SORLA antibody (rabbit polyclonal, Atlas Antibodies; 1:300 dilution) was used and primary antibodies were detected with PowerVision Poly-HRP anti-mouse/anti-rabbit IHC system (Leica BioSystems). Finally, the slides were counterstained with hematoxylin.
IHC staining intensities of each tissue core were visually scored for SORLA as 0 (negative), 1 (weak to moderate), or 2 (strong), and for HER2 and EGFR as 0 (negative), 1 (weak), 2 (moderate) or 3 (strong). SORLA and HER2/EGFR stainings were evaluated independently by two readers and the mean and maximum values of three tissue cores were determined for each patient. In the final statistical analysis, maximum scores for all the stainings were used. 
Tissue microarray construction
Quantification of intracellular HER2 levels
Several fields were randomly imaged with identical microscope settings. ImageJ was used for analysis and quantifications. Intracellular Tz-568 fluorescence signal was analysed from maximal intensity projections of 6 planes taken from the middle of the cell (determined by DAPI signal).
Intracellular endogenous HER2 fluorescence intensity was measured from a single middle plane of the cell. Intracellular signal was quantified by manually gating the intracellular part of the cell and the intracellular signal was measured and normalized to the cell area. Results are pooled from two independent biological replicates.
Quantification of LAMP1 positive late-endosome/lysosome aggregation SORLA silenced and control silenced cells were fixed and stained for LAMP1 (Santa-Cruz, SC-20011) and DAPI as described above. Cells were imaged with identical microscope settings with Carl Zeiss LSM780 laser scanning confocal microscope. The image processing and quantifications were performed with Image J software. The level of LAMP1 positive late-endosome/lysosome aggregation was quantified from the middle plane. To distinguish between individual late-endosome/lysosome aggregates, watershed segmentation was used before quantification. The areas of lateendosome/lysosome aggregates were quantified from a single cell. LAMP1 positive area larger than 5 µm 2 was considered as aggregate. Total area of LAMP1 positive late-endosomes/lysosomes was calculated based on LAMP1 staining as well as the area of aggregates larger than 5 µm 2 . The percentage of lysosomal aggregation was determined by the ratio of area of aggregates larger than 5 µm 2 to total LAMP1 positive late-endosome/lysosome area.
Quantification of Ki-67 and TUNEL positivity in 5637 cell xenografts
Pannoramic viewer (3DHISTECH Ltd) was used to scan histology slides and export images (2x magnification) for image processing and quantifications, which were performed identically for all the samples with ImageJ software. The TUNEL and Ki-67 positive tumor areas were thresholded with MaxEntropy and quantified. The ratio of Ki-67 positive (or TUNEL positive) area to total tumor area was calculated.
Co-localization analysis
Pixel-intensity based Pearson correlation coefficient (R) between two channels was calculated using coloc2 plugin (https://imagej.net/Coloc_2) of ImageJ v1.51s with default parameters. Percentage colocalization between the vesicular particles was done using ComDet 0.3.6.1 (https://github.com/ekatrukha/ComDet) plugin of ImageJ v1.51s. Particles were detected in both channels independently at approximated particle sizes of 4 pixels with sensitivities of signal/noise ratio of 4. Colocalization was determined based on a maximum distance between two particle centers of 5 pixels and expressed as percentage.
Statistical analysis
The GraphPad Prism software and two-tailed Student's t-test (paired or unpaired, as appropriate) was used for statistical analysis. Normal distribution of the data was tested with Shapiro-Wilk normality
